Indian Journal of PsychiatryIndian Journal of Psychiatry
Home | About us | Current Issue | Archives | Ahead of Print | Submission | Instructions | Subscribe | Advertise | Contact | Login 
    Users online: 767 Small font sizeDefault font sizeIncrease font size Print this article Email this article Bookmark this page
Search Again
 Back
 Table of Contents
 
 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Article Access Statistics
 Reader Comments
 Email Alert
 Add to My List
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed576    
    Printed29    
    Emailed0    
    PDF Downloaded79    
    Comments [Add]    

Recommend this journal

 
ARTICLE
Year : 2001  |  Volume : 43  |  Issue : 3  |  Page : 257-263

Olanzapine in the Treatment of Schizophrenia : An Open Label Comparative Clinical Trial from North India


1 Additional Professor, Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh-160012, India
2 Professor & Head, Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh-160012, India
3 Research Associate, Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh-160012, India

Correspondence Address:
Ajit Avasthi
Additional Professor, Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh-160012
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 21407865

Rights and PermissionsRights and Permissions

The aim of the present study was to assess the efficacy and safety of olanzapine in the treatment of schizophrenic patients. 27 patients were randomly assigned to treatment with olanzapine or haloperidol over 12 weeks. The primary efficacy measure was the mean change from baseline to endpoint in total scores on the Brief Psychiatric Rating Scale (BPRS) and assessing treatment emergent adverse events. Secondary measures were positive symptoms, negative symptoms, general psychopathology depression, anxiety and quality of life. Compared to haloperidol, olanzapine had equal effect in improving overall psychopathology, positive symptoms, and severity of schizophrenic illness. Olanzapine showed supehor improvement on negative symptoms and secondary depressive features. Commonest side effects were weight gain, sleepiness and increased duration of sleep. Olanzapine is effective in improving overall psychopathology including positive symptoms, negative and secondary depressive features in Indian patients with schizophrenia and it is safe and well tolerated at dosage between 5 to 20 mg/day



[PDF]*

        

Print this article         Email this article